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Effective clearance of apoptotic cells by macro-
phages is essential for immune homeostasis. The
transcriptional pathways that allow macrophages to
sense and respond to apoptotic cells are poorly
defined.We found that liver X receptor (LXR) signaling
was important for both apoptotic cell clearance and
the maintenance of immune tolerance. Apoptotic
cell engulfment activated LXR and thereby induced
the expression of Mer, a receptor tyrosine kinase crit-
ical forphagocytosis. LXR-deficientmacrophagesex-
hibitedaselectivedefect inphagocytosis of apoptotic
cells and an aberrant proinflammatory response to
them. As a consequence of these defects, mice lack-
ing LXRs manifested a breakdown in self-tolerance
and developed autoantibodies and autoimmune
glomerulonephritis. Treatment with an LXR agonist
ameliorated disease progression in a mouse model
of lupus-like autoimmunity. Thus, activation of LXR
by apoptotic cells engages a virtuous cycle that
promotes their own clearance and couples engulf-
ment to the suppression of inflammatory pathways.
INTRODUCTION
Apoptosis occurs through a series of controlled events that
ensure cellular remnants are contained and eliminated without
initiating an inflammatory immune response (Grimsley and Rav-
ichandran, 2003; Henson et al., 2001; Savill and Fadok, 2000). In
general, apoptotic cell sensing systems recognize lipid or carbo-
hydrate changes displayed on the outside of the dying cell, such
as phosphatidylserine (PtdSer), a membrane lipid normallyrestricted to the inner leaflet of the plasma membrane (Green,
2003; Ravichandran and Lorenz, 2007). The loss of membrane
asymmetry during apoptosis also leads to oxidation of phospho-
lipids. These ‘‘eat-me’’ signals are bound by bridging molecules
including milk fat globule EGF factor 8 (MFGE8), growth-arrest-
specific 6 (GAS6), and complement factor C1q on the surface
of apoptotic cells (Botto et al., 1998; Hanayama et al., 2002; Ish-
imoto et al., 2000). Bridging molecules facilitate phagocytosis
through interaction with specific receptors expressed on macro-
phages and dendritic cells, including the TAM family of receptors
(Tyro3, Axl, and Mer), avb3-integrin, Tim4, and CD36 (Fadok
et al., 1998a; Lemke and Rothlin, 2008; Miyanishi et al., 2007;
Ravichandran and Lorenz, 2007).
After apoptotic cell engulfment, macrophages activate tolero-
genic pathways in an effort to prevent immune responses
against self-antigens (Henson and Hume, 2006; Taylor et al.,
2005). Tolerance is accomplished through several distinct mech-
anisms, including suppression of inflammatory cytokine produc-
tion and release of anti-inflammatory cytokines such as IL-10
and TGF-b (Fadok et al., 1998b; Li and Flavell, 2008; Voll et al.,
1997). If phagocytosis or tolerogenic pathways are impaired,
chronic accumulation of free apoptotic material can have patho-
logical consequences (Henson and Hume, 2006; O’Shea et al.,
2002). The resulting inflammation and stimulation of adaptive
immune responses against self-antigens may ultimately trigger
autoimmunity (Ravichandran and Lorenz, 2007; Savill et al.,
2002). Interestingly, TAM receptors have recently been linked
to the suppression of TLR signaling, revealing one mechanism
by which apoptotic cell clearance and immune tolerance are
coupled (Lemke and Rothlin, 2008; Rothlin et al., 2007). Tran-
scriptional pathways integrating apoptotic cell clearance and
the immunosuppressive effects of apoptotic cells remain to be
characterized.
Liver X receptors (LXRa and LXRb) are oxysterol-activated
transcription factors that sense elevated cellular cholesterolImmunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 245
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of excess lipoprotein-derived cholesterol in macrophages acti-
vates LXR and triggers the induction of a transcriptional program
for cholesterol efflux (Castrillo and Tontonoz, 2004). Pharmaco-
logically activated LXRs have also been shown to transrepress
inflammatory gene expression (Castrillo et al., 2003a; Ghisletti
et al., 2007; Joseph et al., 2003). However, the physiological rele-
vance of endogenous transrepression pathways has remained
unclear, because no biological processes have been definitively
shown to be dependent on both activation and transrepression.
We reasoned that the dual abilities of LXRs to respond to phago-
cytosed lipids and to modulate inflammation places them in
an ideal position to tailor macrophage responses to particular
phagocytic contexts. We found that the LXR pathway was
essential for efficient apoptotic cell clearance through positive
induction of Mer, as well as for the maintenance of immune toler-
ance through transrepression of inflammation in response to
phagocytosis. These results implicate LXRs in a positive tran-
scriptional feedback loop that couples apoptotic cell clearance
with the suppression of autoimmunity.
RESULTS
Defective Phagocytosis of Apoptotic Cells
in LXR-Deficient Macrophages
Previous work has established that LXRa and LXRb (encoded by
the genesNhr1h3 andNhr1h2) are important for the macrophage
response to lipoprotein uptake (Castrillo and Tontonoz, 2004),
but their impact on other phagocytic processes is unknown. To
investigate a possible role of LXRs in apoptotic cell clearance,
thioglycollate-elicited macrophages obtained from wild-type
(WT) and LXR-deficient mice lacking both LXRa and LXRb
proteins (LXR DKO) mice were cocultured in vitro with apoptotic
thymocytes (ATs). Engulfed ATs were differentiated from associ-
ated ATs through use of a cell dissociation buffer (Krysko et al.,
2006) and by scoring engulfed cells by confocal microscopy
(Figures 1A and 1B). We found that ATs were efficiently engulfed
by WT macrophages, whereas phagocytosis by LXR-deficient
macrophages was markedly reduced. By contrast, phagocytosis
of GFP-E. coli or fluorescent microspheres was comparable in
WT and LXR DKO macrophages, indicating that loss of LXR
function does not lead to a general defect in phagocytosis
(Figure S1 available online). To determine whether apoptotic
cell clearance could be improved by exogenous stimulation of
LXR activity, macrophages were cultured with the synthetic
LXR agonist GW3965 (Collins et al., 2002) for 48 hr and then chal-
lenged with apoptotic cells for 1 hr. GW3965 enhanced WT
macrophage phagocytosis but had no effect in macrophages
lacking LXRs (Figures 1C and 1D).
These LXR-dependent mechanisms appear to function in vivo,
too. Resident macrophages of LXR-deficient mice exhibited
reduced AT association (combination of bound and engulfed
cells) in response to intraperitoneal injection of CFSE-labeled
ATs compared to macrophages of C57BL/6 mice (Figure 1E).
Furthermore, primary macrophages from mice treated with
GW3965 for 3 days displayed increased AT association
compared to vehicle-treated mice (Figure S2). AT association
in this assay was specific for macrophages, as indicated by
the fact that we observed no association of ATs with peritoneal246 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.B cells (Figure S3A). Furthermore, defective AT association of
LXR DKO macrophages could not be attributed to loss of regu-
lation of the established LXR targets Abca1, Abcg1, or Apoe,
because mice lacking expression of these genes showed
comparable AT association to WT cells (Figures S3B and S3C).
Note, Abca1 null mice on a C57Bl/6 background are not viable
and therefore comparison was made to background-matched
Abca1+/+ controls (Figure S4C). LXR-dependent regulation of
AT phagocytosis was also observed in both immature and
mature dendritic cells (Figure S3D). Thus, loss of LXR functions
alters the phagocytic capacity of both macrophages and
dendritic cells.
Altered Macrophage Functions in LXR-Deficient
Lymphoid Tissues
Next we investigated the potential consequences of loss of LXR
function for apoptotic cell clearance in vivo. Immunofluores-
cence analysis of LXR DKO spleens showed increased numbers
of germinal centers staining with peanut agglutinin (PNA) and
increased numbers of immunoglobulin G (IgG)-producing cells
(Figure 2A). In addition, LXR DKO spleens showed an anomalous
distribution of CD68+ ‘‘tingible body’’ macrophages (Rabinowitz
and Gordon, 1991). Staining of endothelial sinus-lining cells with
MadCAM-1 also demonstrated defects in the organization of the
spleen in older LXR-deficient mice (Figure 2A). Macrophages
present in germinal centers participate in the clearance of
apoptotic B cells (Smith et al., 1991; Taylor et al., 2005). Accord-
ingly, few apoptotic cells were typically observed in the spleens
of WT mice, and these colocalized with macrophages (Figure 2B,
left). In contrast, despite comparable numbers of splenic CD68+
macrophages (data not shown), many free apoptotic bodies
were present in LXR DKO spleens, consistent with inefficient
macrophage engulfment (Figure 2B, right). Free apoptotic
bodies were also observed in several other tissues of LXR
DKO mice, including thymus, lung, and testis (Figure S4A). We
have previously reported that macrophages lacking LXR expres-
sion undergo apoptosis when challenged with Listeria monocy-
togenes (Joseph et al., 2004). However, LXR DKO macrophages
did not undergo apoptosis at an increased rate compared to WT
when challenged with ATs. The apoptotic bodies observed in
LXR DKO spleens colocalized with B cells (Figure S4B) but not
with macrophages (Figure 2B). Furthermore, LXR DKO macro-
phages challenged with ATs in vitro for extended times (18 hr)
did not undergo apoptosis as assayed by TUNEL staining
(Figures S4C and S4D and data not shown).
We also evaluated the clearance of dying thymocytes after
dexamethasone (dex)-induced apoptosis in vivo. Both WT and
LXR DKO thymocytes showed comparable sensitivity to dex-
or UV irradiation-induced apoptosis in vitro (Figure S5). After
24 hr of dex stimulation, thymi of WT mice showed a marked
loss of mass and few Annexin V+ cells, consistent with effective
clearance of apoptotic cells (Figure 2C). By contrast, despite
similar recruitment of CD68+ macrophages, LXR DKO thymi con-
tained increased numbers of free Annexin V+ cells and mass was
not altered. In agreement with these results, transmission elec-
tron microscopy analysis of thymic sections revealed effective
engulfment of apoptotic bodies by WT macrophages (Figure 2D;
see inset, a macrophage with five apoptotic cells inside),
whereas abundant clusters of free apoptotic cells (large dark
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LXR Signaling in Phagocytosis and Autoimmunitystaining bodies) were observed in LXR DKO mice. Thus, loss of
LXR function results in defective clearance of apoptotic cells
in vivo.
Transcriptional Regulation of Genes Involved
in Clearance of Apoptotic Cells by LXRs
To identify LXR target genes involved in the removal of apoptotic
cells, we conducted transcriptional profiling studies by using
RAW264.7 cells ectopically expressing LXRa (Venkateswaran
et al., 2000) (RAW-LXRa; Figure S6A). These studies identified
the gene encoding the Mer receptor tyrosine kinase (Mertk) (Ca-
menisch et al., 1999; Graham et al., 1995) as an LXR-responsive
gene (Figure S6B). Mer plays an important role in the clearance of
dying cells through interaction with PtdSer-bound Gas6 on the
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Figure 1. LXR Signaling Regulates Phago-
cytosis of Apoptotic Cells
(A) Decreased engulfment of apoptotic thymo-
cytes by macrophages deficient in LXRa and
LXRb proteins (LXR DKO) in vitro as visualized by
phagocytosis of CellTracker Green CMFDA-
labeled ATs. A cell dissociation buffer (Krysko
et al., 2006) was added to distinguish engulfed
from bound cells as indicated. Arrows indicate
attached cells. CellTracker Green CMFDA-labeled
ATs were cultured with macrophages (stained with
CellTracker Red CMTPX) for 1 hr. In this and all
subsequent experiments, a ratio of 5 ATs:1 macro-
phage was used. Attached and engulfed cells
were distinguished by extensive washing with
cold PBS and Enzyme Free Cell Dissociation
Buffer to remove free ATs. Macrophage phagocy-
tosis was evaluated by fluorescence microscopy.
(B) Quantification of phagocytosis by confocal
microscopy after incubation of apoptotic thymo-
cytes (ATs) for 0.5, 1, or 2 hr with WT or LXR
DKO macrophages.
(C and D) LXR agonist promotes phagocytosis of
labeled ATs as shown by confocal microscopy.
Thioglycolate-elicited peritoneal macrophages
from WT or LXR DKO mice were pretreated with
vehicle or 1 mM GW3965 for 48 hr and then incu-
bated with apoptotic cells for 1 hr.
(E) In vivo association of CFSE-labeled apoptotic
cells with LXR DKO macrophages was determined
by flow cytometry. Results from three separate
mice are shown for each genotype.
All experiments were repeated a minimum of three
times with comparable results. Statistical analysis
was performed via Student’s t test. *p < 0.05, **p <
0.01. Error bars in this and all subsequent figures
represent mean ± SD.
surface of apoptotic cells (Cohen et al.,
2002; Lemke and Rothlin, 2008; Scott
et al., 2001). Real-time PCR and immuno-
blot analysis of RAW-LXRa cells and
primary macrophages confirmed that
Mertk was a bona fide LXR-responsive
gene (Figures 3A–3C). Expression of
Mertk was induced by LXR and RXR
agonists in WT, LXRa-deficient, and
LXRb-deficient but not in LXR DKO
primary macrophages (Figure 3B; Figure S6B), indicating that
Mertk responds to both LXRa and LXRb. Expression of the other
members of the TAM family, Tyro3 and Axl, was not altered by
LXR agonists (Figure S6A and data not shown). Although several
different RXR heterodimeric nuclear receptors are expressed
in macrophages, the effect of RXR agonists on Mer expres-
sion was absolutely dependent on LXR expression (Figures 3B
and 3C).
Importantly, Mer expression was also responsive to LXR acti-
vation in vivo. Treatment for 3 days with GW3965 induced
expression of Mer in spleen and lung of WT but not LXR DKO
mice (Figure 3D). Basal expression of Mertk mRNA was also
impaired in primary cells and lymphoid organs of LXR DKO
mice (Figures 3C and 3D and not shown). To determine whetherImmunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 247
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Figure 2. Defective In Vivo Clearance of Apoptotic Cells in LXR-Deficient Lymphoid Tissues
(A) Spleen sections from 40-week-old WT and LXR DKO mice were stained with fluorescein-labeled peanut agglutinin (PNA), IgG, mucosal addressin cell adhe-
sion molecule (MAdCAM-1), and B220 as indicated.
(B) Representative spleen sections (4 mm) from 40-week-old WT and LXR DKO mice were analyzed by TUNEL staining (green) and staining for CD68+ macro-
phages (red). Free apoptotic cells are indicated by arrows (right). Scale bar represents 25 mm.
(C) 4-week-old male WT and LXR DKO mice (4 animals/group) were injected with 0.2 mg dexamethasone (dex) and thymi were isolated 24 hr later. Thymic mass
was measured in each mouse after 24 hr of dex. The percentage of Annexin V+/Tunel+ cells and recruitment of macrophages was evaluated in cell suspensions by
flow cytometry. **p < 0.001.
(D) Thymic sections were analyzed by transmission electron microscopy.the Mertk gene was a direct target for LXRs, we analyzed the
50-promoter region. A potential LXRE (LXR response element)
was identified 1.7 kb upstream of the transcription start site
(Figure S7A). Electromobility shift assays demonstrated that
in vitro translated LXR and RXR proteins bound as heterodimers
to a radiolabeled oligonucleotide containing this element (Fig-
ure S7A). Binding of LXR to the Mertk promoter was also con-
firmed by chromatin immunoprecipitation (ChIP) analysis of
RAW-FLAG-LXRa cells (Figure S7B). ChIP assays with either
FLAG or RXRa antibodies demonstrated the presence of LXR/
RXR heterodimers on theMertkpromoter. Furthermore, GW3965
caused release of N-CoR from and recruitment of RNA poly-
merase II to both the Mertk and Srebp-1c promoters in RAW-
LXRa cells (Figure S7C).248 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.Ingestion and degradation of apoptotic cells by macrophages
leads to the accumulation of cellular components, including
cholesterol. We hypothesized that such accumulation might
activate LXR signaling. Remarkably, expression of Mertk and
a battery of known LXR targets (Abca1, Abcg5, Pltp, and
Scl2a4), was induced by apoptotic thymocytes in WT macro-
phages (Figure 3A). By contrast, induction of these genes by
ATs was severely impaired LXR DKO macrophages. Some
residual induction of Mertk by ATs remained in LXR DKO macro-
phages, pointing to the contribution of an additional, LXR-inde-
pendent pathway. Genes not regulated by LXR, such as Cd36,
were induced by ATs to comparable degrees in both WT and
LXR DKO macrophages (Figure 3A). Expression of Mfge8 was
not responsive to AT or LXR signaling. Thus, LXR mediates the
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Figure 3. Apoptotic Cells Promote Mer Expression and Phagocytosis through LXR-Dependent Pathways
(A) Thioglycolate-elicited peritoneal macrophages from WT or LXR DKO mice were treated with vehicle, 1 mM GW3965 (GW), or ATs (ratio of 5 ATs:1 macrophage)
for 24 hr. Gene expression was measured by real-time PCR. *p < 0.05 versus vehicle control; xp < 0.05 versus WT control. Experiment was repeated three times
with comparable results.
(B) LXR-dependent regulation of Mertk expression in peritoneal macrophages. mRNA expression was assayed in WT, LXRa-deficient, LXRb-deficient, or LXR
DKO macrophages treated for 24 hr with 1 mM GW3965 and/or 100 nM of the LXR agonist LG268 (LG).
(C) Induction of Mer protein expression by LXR and RXR agonists in primary WT and LXR DKO macrophages.
(D) Induction of Mertk expression in vivo. mRNA expression was evaluated in spleen and lung tissues from WT and LXR DKO mice treated with GW agonist for
3 days. n = 5 per group. *p < 0.05.
(E) Apoptotic cells promote their own uptake in an LXR-dependent manner. WT or LXR DKO macrophages were challenged with CMFDA-labeled ATs for 90 min.
3 or 24 hr later, the same macrophages were challenged with a second round of CMTPX-labeled ATs for 90 min and only CMTPX-labeled engulfed cells were
scored as in Figure 1. *p < 0.05.
(F) Depletion of cellular sterols from ATs inhibits their ability to activate LXR. Sterol content from ATs was decreased by treating cells with 5 mM methyl-beta-
cyclodextran (MbCD) prior to addition to macrophages. Macrophages were cultured with untreated or sterol-depleted ATs for 90 min. Unengulfed cells were
removed and gene expression was measured by real-time PCR after 24 hr.
Graphs represent mean ± SD. Data are representative of a minimum of three independent experiments.Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 249
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in phagocytosis and lipid metabolism. These results suggest
that engulfment of apoptotic cells leads to activation of LXRs
and the promotion of Mer expression, providing positive feed-
back to facilitate further apoptotic cell uptake. In support of
this idea, we found that macrophages challenged with one round
of ATs show increased phagocytic capacity when challenged
with a second round, and that this response was dependent
on LXR expression (Figure 3E). Furthermore, depletion of sterols
from ATs by means of methyl beta-cyclodextran treatment
reduced their ability to induce LXR target gene expression
(Mertk, Abca1) after ingestion by macrophages, but not their
ability to induce Marco or Cd36 expression. These results
strongly suggest that cholesterol and/or oxysterol species
present in ATs can serve as LXR agonists (Figure 3F). In support
of this idea, Lauber et al. (2003) have previously reported that
lipid mediators derived from apoptotic cells are important for
efficient engulfment of dying corpses.
Proinflammatory Signaling in Response to Apoptotic
Cells in LXR-Deficient Mice
Engulfment of apoptotic cells is coupled to the suppression
of inflammatory pathways in order to avoid unwanted immune
responses against intracellular antigens. Interestingly, both
A B
C
Figure 4. LXRsMediate Tolerogenic Effects
of Apoptotic Cells
(A) Thioglycolate-elicited peritoneal macrophages
from WT or LXR DKO mice were treated with
vehicle or ATs (ratio of 5 ATs:1 macrophage) for
24 hr. Gene expression was measured by real-
time PCR. *p < 0.05 versus vehicle control; xp <
0.05 versus WT control.
(B) Macrophages from WT and LXR DKO mice
were challenged with ATs for 24 hr and mRNA
expression was evaluated by northern blotting.
(C) Exposure to apoptotic cells inhibits macro-
phage responses to LPS in an LXR-dependent
manner. WT or LXR DKO macrophages were pre-
incubated with ATs for 1 hr and then challenged
with LPS for 3 and 6 hr. Gene expression was eval-
uated by real-time PCR. *p < 0.05.
Graphs represent mean ± SD. Data are represen-
tative of a minimum of three independent experi-
ments.
Mer and LXR have previously been im-
plicated in the repression of macro-
phage inflammatory signaling (Came-
nisch et al., 1999; Joseph et al., 2003;
Rothlin et al., 2007). Based on the
abnormal phagocytic response of LXR-
deficient mice to apoptotic cells, we pre-
dicted that regulation of inflammatory
pathways during the engulfment process
might be also altered in LXR DKO macro-
phages. We therefore tested the ability
of apoptotic cells to engage anti-inflam-
matory mechanisms in the presence or
absence of LXR. In agreement with
previous studies (Fadok et al., 1998b; Voll et al., 1997), ATs
promoted the expression of immunosuppressive mediators
such as TGF-b and IL-10 in WT macrophages (Figures 4A and
4B). However, induction of these genes was impaired in macro-
phages lacking LXRs. Furthermore, inadequate engulfment of
apoptotic cells by LXR-deficient macrophages led to the inap-
propriate expression of proinflammatory mediators, such as
IL-1b and MCP-1, and enhanced induction of Marco (Figures 4A
and 4B). LXR agonist alone repressed basal expression of the
genes encoding IL-1b and MCP-1, but did not induce expression
of those encoding TGF-b or IL-10 (Figure S8A and data not
shown).
We also tested the ability of apoptotic cells to counteract
inflammatory signaling induced by ligands for toll-like receptors
(TLR) 2, 3, and 4 (Figure 4C; Figure S8B). Culturing primary
WT macrophages with ATs inhibited the stimulus-dependent
induction of genes encoding IL-12p40 and IL-1b, in agreement
with previous work (Fadok et al., 1998b; Voll et al., 1997). By
contrast, incubation of apoptotic thymocytes with LXR-deficient
macrophages resulted only in partial repression of inflammatory
gene expression induced by LPS and other TLR activators (Fig-
ure 4C; Figure S8B). Thus, LXR signaling couples the engulf-
ment of apoptotic cells to the suppression of inflammatory
pathways.250 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.
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Figure 5. Mer Expression Is Required for LXR-Dependent Phagocytosis of Apoptotic Cells
(A) Protein expression in RAW cells stably expressing LXRa (RAW-LXRa) or Mer (RAW-Mer).
(B) Phagocytosis of apoptotic cells was evaluated in RAW-LXRa or RAW-Mer macrophages. Cells were treated for 36 hr with GW3965 and then challenged with
ATs for 15, 45, and 90 min.
(C) A blocking antibody to Mer inhibits AT uptake in WT but not LXR-deficient macrophages. Thioglycolate-elicited peritoneal macrophages from WT or
LXR-deficient mice were incubated with either IgG control antibody or Mer-specific blocking antibody for 3 hr. Phagocytosis of apoptotic cells was evaluated
by confocal microscopy after 90 min incubation of ATs. n = 3. **p < 0.01.
(D) RAW macrophages were transfected with control or Mer-specific siRNAs. Protein expression was determined by immunoblotting.
(E) Primary mouse peritinoeal macrophages were transfected with control or Mer-specific siRNAs. AT phagocytosis after 90 min incubation was quantitated by
confocal microscopy.
(F) RAW macrophages were transfected with control or Mer-specific siRNAs. AT phagocytosis after 90 min incubation was quantitated by confocal microscopy.
(G) Primary mouse peritoneal macrophages were transfected with indicated siRNAs. Efficacy of control, Mer-, ApoE-, and Abca1-specific siRNAs on protein
expression was determined by immunoblotting.
(H) Primary macrophages were transfected with siRNA and AT phagocytosis after 90 min incubation was quantitated by confocal microscopy. *p < 0.05;
**p < 0.001.
Graphs represent mean ± SD. Data are representative of a minimum of three independent experiments.LXR-Dependent Expression of Mer Promotes Apoptotic
Cell Clearance in Macrophages
To further evaluate the role of Mer in LXR-dependent responses
to apoptotic cells, we performed gain-of-function experiments.
Retroviral expression of LXRa in RAW264.7 cells promoted the
engulfment of ATs in response to GW3965 (Figures 5A and 5B).
Ectopic expression of Mer itself also enhanced the phagocytosis
of apoptotic cells, but this effect was not markedly modified by
the addition of GW3965 (Figures 5A and 5B). Treatment of WT
macrophages with a Mer-blocking antibody (Sen et al., 2007)decreased AT phagocytosis to a similar degree to that observed
in LXR-deficient macrophages (Figure 5C). To provide direct
evidence for a link between LXR activation, Mer, and phagocy-
tosis, we performed knockdown studies. RAW-LXRa cells
were transfected with nonspecific or several different Mer-
specific siRNAs (Figure 5D) and assayed for phagocytic activity.
Reduction of Mer expression inhibited phagocytosis induced by
LXR ligand, whereas nonspecific siRNA had no effect in both
primary mouse macrophages and RAW cells (Figures 5E and
5F). To further confirm the role of the LXR-Mer pathway, weImmunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 251
Immunity
LXR Signaling in Phagocytosis and Autoimmunityperformed additional knockdown studies in primary macro-
phages. Protein knockdown was verified by immunoblotting
(Figure 5G). Reduction in Mer expression effectively inhibited
the effect of LXR agonist on AT uptake, whereas knockdown of
ABCA1 and apoE did not (Figure 5H). These data show that
LXR signaling promotes the clearance of apoptotic cells, at least
in part, through induction of Mer expression.
LXR-Deficient Mice Develop Age-Dependent Systemic
Autoimmune Disease
Finally, we hypothesized that improper regulation of Mer expres-
sion and defective clearance of apoptotic cells would have path-
ological consequences for mice lacking LXRs. Analysis of
lymphoid tissues from LXR-deficient mice revealed age-depen-
dent splenomegaly (Tangirala et al., 2002), lymphadenopathy,
and increased total cell numbers in these organs (Figures 6A
and 6B). A marked increase in the frequency and absolute
numbers of CD19+B220+ B cells was observed in spleens and
lymph nodes of LXR DKO mice (Figures S9 and S10). The
massive lymphadenopathy observed in older LXR DKO mice is
reminiscent of the MRLlpr/lpr phenotype. However, we did not
observe the accumulation of CD3+B220+DN T cells character-
istic of MRLlpr/lpr mice in LXR DKO mice (Figure S11). Further-
more, lymphoproliferative disease in LXR DKO mice did not
appear to be a consequence of the loss of CD4+CD25+FoxP3+
regulatory T cells (Figure S11). Defects in Mer signaling have
previously been reported to result in the loss of self-tolerance
and lupus-like disease (Cohen et al., 2002; Scott et al., 2001).
Accordingly, elevated quantities of antibodies to nuclear
proteins (ANA, antinuclear antibodies), double-stranded DNA
(dsDNA), and histones were detected in the serum of LXR DKO
mice (Figure 6C).
A major pathogenic consequence of autoantibody production
is the deposition of immune complexes in the kidney, leading to
glomerulonephritis. Examination of kidney sections from WT and
LXR-deficient mice revealed conserved renal architecture in
both genotypes (Figure 6D and data not shown). However,
LXR DKO mice exhibited glomerular enlargement, mesangial
proliferation, and glomerular basement membrane thickening
(Figure 6D). Immunofluorescence microscopy revealed marked
age-dependent glomerular deposition of IgG-containing
immune complexes and an inflammatory infiltrate of macro-
phages, B cells, and T cells in kidneys of LXR DKO but not WT
mice (Figures 6E–6G; Figure S12A). This observation is consis-
tent with the development of age-dependent autoimmune
disease resulting from autoantibody production. Moreover, the
pathological changes in LXR DKO mice were associated with
compromised renal function. Alterations in diuresis and urea
excretion as well as markedly increased urinary protein concen-
trations were observed in a majority of 40-week-old LXR DKO
mice (Table S1). We also observed immunoglobulin deposition
in multiple other tissues including lung and skin of LXR DKO
mice, consistent with systemic autoimmune disease (Figures
S12B and S12C).
Full manifestation of the autoimmune phenotype required
the combined deletion of both LXRa and LXRb, consistent with
the idea that macrophages (which express both LXRs) rather
than lymphocytes (which express only LXRb) are the primary
cause of this pathology (Figure S13A). Accordingly, the dramatic252 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.lymphoid hyperplasia and marked defects in apoptotic cell
uptake and repression of inflammatory gene expression were
observed only in mice and cells lacking both LXRa and LXRb
(data not shown). The autoimmune phenotype of LXR-deficient
mice is highly reminiscent of that of Mertk/ mice (Cohen
et al., 2002). By contrast, similar disease was not observed in
background-matched mice lacking the previously described
LXR target genes Apoe and Abcg1 (Figure S13A). We also did
not observe an increase in immunoglobulin deposition in
Abca1/ mice compared to background-matched controls
(Figure S13B). Thus, it does not appear that loss of either
Abca1 or ApoE alone can explain the autoimmune phenotype
of the LXR DKO mice.
LXR Activation Ameliorates Lupus-like Autoimmune
Disease in Mice
Finally, we investigated whether pharmacological activation of
LXR altered the development of autoimmune disease. Macro-
phages derived from B6lpr/lpr mice exhibited reduced phagocytic
capacity compared to controls, consistent with prior work (Licht
et al., 2004; Potter et al., 2003; Qian et al., 2006). Remarkably,
treatment of B6lpr/lpr macrophages with LXR agonist restored
both phagocytic capacity and Mer expression to above basal
control levels (Figures 7A and 7B). To determine whether
systemic administration of LXR agonist could ameliorate autoim-
mune disease, female B6lpr/lpr mice were treated for 4 months
with GW3965. Positron emission tomography and computed
tomography (PET and CT) imaging revealed a marked decrease
in lymphadenopathy in GW3965-treated animals (Figure 7C).
Visual inspection of the lymph nodes found 90% decrease in
total cellularity (Figure 7D). FACS analysis did not reveal any
substantial differences in the frequency of specific immune cells
in LN and spleen (data not shown). Although the extent of renal
disease is mild on the B6 background, LXR nevertheless
substantially reduced glomerular antibody deposition in B6lpr/lpr
mice (Figure 7E). Collectively, these results indicate that an intact
LXR signaling pathway is important for Mer expression,
apoptotic cell clearance, and the maintenance of immune toler-
ance, and that pharmacologic activation of LXR antagonizes the
pathogenesis of autoimmune disease.
DISCUSSION
The balance between cell death and cell survival is crucial for
tissue homeostasis in multicellular organisms (Green, 2003).
Unwanted cells are usually eliminated by apoptosis, a pro-
grammed cellular suicide conserved from worms to mammals
that culminates in recognition and ingestion of dying cells by
phagocytes (Henson and Hume, 2006; Ravichandran and Lor-
enz, 2007). In contrast to other types of phagocytosis, such as
bacterial or necrotic cell uptake, scavenging of apoptotic cells
is immunologically silent (Lauber et al., 2004). Efficient disposal
of apoptotic corpses prevents uncontrolled release of intracel-
lular contents and is important for immunological self-tolerance
(Ravichandran and Lorenz, 2007). Intracellular pathways that
link the engulfment of apoptotic corpses and suppression of
inflammation are incompletely characterized. We have shown
here that the nuclear receptor LXR is important for both
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Figure 6. LXR-Deficient Mice Develop Autoimmune Disease
(A) Spleen mass in WT and LXR-deficient mice. Spleens were isolated from WT and LXR DKO mice at the indicated age and spleen mass relative to body weight
was measured. n = 6 per group.
(B) Total cell counts from spleen and lymph node of 40-week-old mice.
(C) 1:100 dilutions of serum samples obtained from 40-week-old WT (12 female mice) and LXR-deficient (8 female mice) were analyzed for the presence of auto-
antibodies by ELISA. Dots represent individual animals, line represents mean.
**p < 0.01, ***p < 0.001. Graphs represent mean ± SD.
(D) Kidney sections (4 mm) from 40-week-old WT and LXR DKO female mice stained with H&E. Scale bars represent 50 mm in the top panel and 25 mm in the
bottom panel.
(E) Kidney sections from 40-week-old female mice stained with FITC-labeled anti-mouse IgG. Scale bar represents 50 mm.
(F) Consecutive kidney sections from 40-week-old female mice were stained with anti-mouse CD4, B220, CD68, and H&E. Scale bar represents 50 mm.
(G) Kidney sections from 40-week-old WT and LXR-deficient female mice stained with CD8 and CD4 antibodies. Scale bar represents 25 mm.
Representative images are shown.Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 253
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Figure 7. Treatment with an LXR Agonist Ameliorates Autoimmune
Disease in Mice
(A) Peritoneal macrophages obtained from WT and B6lpr/lpr mice were treated
with GW3965 for 24 hr. Phagocytosis was measured by confocal microscopy.
(B) Gene expression in macrophages from WT and B6lpr/lpr mice treated as in
(A) determined by real-time PCR.
(C) L-FMAC and PET and CT imaging of B6lpr/lpr mice. Images were analyzed
with AMIDE software. n = 5/group; representative images are shown.254 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.apoptotic cell clearance and suppression of the inflammatory
response during their phagocytosis.
Prior work has shown LXR to be critical for macrophage
cholesterol homeostasis (Castrillo and Tontonoz, 2004; Repa
and Mangelsdorf, 2002). In response to lipoprotein uptake via
scavenger receptors, macrophages activate an LXR-dependent
pathway for cholesterol efflux. Unexpectedly, we found that
phagocytosis of apoptotic cells also activates LXR, likely through
the accumulation of membrane-derived cholesterol. LXR in turn
activates transcription of Mer, thereby providing positive feed-
back to promote further clearance, as well as genes such as
Abca1 and Abcg1 to promote efflux of the excess cholesterol
(Tontonoz and Mangelsdorf, 2003). At the same time, LXR acti-
vation in response to apoptotic cells also suppresses the
production of inflammatory mediators. Because cholesterol is
not a component of pathogens such as bacteria, activation of
LXR by apoptotic cell-derived cholesterol provides a mechanism
to suppress inflammatory responses in some phagocytic path-
ways but permit them in others.
Collectively, our data provide a new physiological context in
which to view the dual activation and transrepression functions
of LXR. Activation of genes such asAbca1 fits well with the estab-
lished function of this receptor in cholesterol homeostasis. The
biological significance of LXR’s transrepressive function,
however, has been less clear. Is the ability to repress inflamma-
tory gene expression related to cholesterol metabolism, or is
this an activity that evolved for a completely separate purpose?
We have shown that the process of apoptotic cell clearance inte-
grates both direct gene activation and transrepression and that,
at least in this context, inhibition of inflammatory gene expression
is intimately linked to metabolism of apoptotic cell lipids. These
results illustrate that the activation and transrepression functions
of LXR are both important for normal immune homeostasis.
Considerable data support the idea that defective clearance of
apoptotic cells leads to autoimmunity (Henson and Hume, 2006;
Savill et al., 2002; Vaux and Flavell, 2000). For example, SLE
patients exhibit an impaired ability to clear apoptotic cells, and
corpses and DNA remnants are found in their serum (Herrmann
et al., 1998; Kalden, 1997; Licht et al., 2004). In mice lacking
Mfge8, Mer, or C1q, lupus-like manifestations have been linked
to inefficient removal of apoptotic cells (Botto et al., 1998; Cohen
et al., 2002; Hanayama et al., 2004). We have shown that loss of
LXR-dependent regulation of Mer and inappropriate activation
of inflammatory signaling during phagocytosis leads to the devel-
opment of autoimmune disease. Interestingly, Mertk/ and LXR
DKO mice share a number of striking similarities, including exac-
erbated inflammatory responses and increased susceptibility to
both autoimmunity and atherosclerosis (Ait-Oufella et al., 2008;
Camenisch et al., 1999; Cohen et al., 2002; Joseph et al., 2003;
Thorp et al., 2008). At the same time, the fact that autoimmune
disease is more severe in LXR DKO compared to Mer-deficient
mice suggests that more than one LXR-dependent pathway
may be involved. We have recently shown that loss of LXRb leads
(D) Lymph node cellularity in 8-week-old B6lpr/lpr female mice treated for
4 months with GW3965. n = 5/group.
(E) Representative kidney sections from female B6lpr/lpr mice treated with
GW3965 for 4 months. Sections were analyzed by anti-immunoglobulin staining.
Scale bar represents 50 mm. n = 6 per group. Representative images are shown.
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likely that the phenotype of LXR DKO mice reflects both the action
of LXRaand LXRb in antigen-presenting cells as well as the auton-
omous effect of LXRb in lymphocytes. It is also possible that loss
of regulation of ABCA1, ApoE (Grainger et al., 2004; Hamon et al.,
2000), and other targets contributes to the autoimmune pheno-
type of LXR-deficient mice. The question of whether defects in
the LXR signaling pathway may contribute to the development
of human autoimmune disease remains to be investigated.
Finally, we have shown that pharmacological LXR activation
has beneficial effects on the progression of autoimmune disease
in mouse models of lupus-like disease. A previous study re-
ported that a different LXR agonist slowed the development of
disease in an experimental autoimmune encephalomyelitis
model, although the underlying mechanism was not addressed
(Hindinger et al., 2006). Our studies indicate that LXR activation
may compensate for the macrophage phagocytic defect charac-
teristic of lupus-like autoimmunity. In addition, it is likely that the
ability of LXRs to directly suppress inflammation and inhibit
lymphocyte proliferation also contribute to the therapeutic
effects of LXR agonists in these disease models. Further studies
will be required to explore the possibility that LXR agonists may
have utility in the therapy of human autoimmune disease.
EXPERIMENTAL PROCEDURES
Animals
LXR-sufficient (Nhr1h3+/+Nhr1h2+/+) and LXR-deficient (Nhr1h3/Nhr1h2/)
mice on mixed Sv129/C57Bl/6 and C57Bl/6 (backcrossed more than ten
generations) backgrounds were provided by David Mangelsdorf (UTSW)
(Peet et al., 1998). C57Bl/6Apoe/ mice were purchased from Jackson Labo-
ratories. C57Bl/6 Abcg1/ and Sv129/C57Bl/6 Abca1/ mice and their WT
controls have been described previously (Kennedy et al., 2005; Timmins
et al., 2005). Mice congenic for the spontaneous mutation Faslpr (B6lpr/lpr)
were purchased from the Jackson Laboratory. For LXR ligand treatment
in vivo, WT or autoimmune-prone mice were fed a standard chow diet with
or without 20 mg/kg/day GW3965. Age-matched female B6lpr/lpr mice were
maintained on diet for 4 months. For imaging studies, mice were sedated
and injected with PET probe L-FMAC, and PET/CT imaging was performed
as previously reported (Radu et al., 2008). Images were analyzed with AMIDE
software. All mice were maintained under pathogen-free conditions in the
animal facilities of the University of California, Los Angeles (UCLA) and Univer-
sity of Las Palmas (ULPGC). Urine samples were collected from individual
metabolic cages (kindly donated by L. Fernandez-Perez) and analyzed at the
Servicio de Bioquimica Hospital Insular. All animal studies were conducted
in accordance with the UCLA and ULPGC Animal Research Committees.
Reagents
The following antibodies and conjugates were used in this study: Mucosal ad-
dressin cell adhesion molecule (MAdCAM-1, eBioscience) CD68 (clone FA-11;
Serotec), anti-CD4 (clone H129.19; BD PharMingen), anti-CD8a (clone 53-6.7;
BD PharMingen), anti-CD45R (B220, clone RA3-6B2; Ebioscience), anti-
mouse-Mer (R&D Systems), Alexa Fluor 647-anti-F4/80 (clone BM8; eBio-
sciences), rat anti-mouse F4/80 (kindly provided by S. Gordon and M. Stacey),
anti-CD11b-FITC (Clone m1/70; PharMingen), anti-mouse-IgG-FITC (Sigma),
Alexa Fluor 488-anti-rat-IgG and IgM (Molecular Probes), Alexa Fluor 594-
anti-rat-IgG and IgM (Molecular probes), Alexa Fluor 350-anti rat-IgG, and
anti-rat byotinilated immunoglobulin (Dako Cytomation). Anti-mouse CD25
(PC61), CD3 (2C11), CD4 (RM4-5), CD8 (53-6.7), CD28 (37.51), CD69
(HI.2F3), Foxp3 (FJK-16 s), CD19 (1D3), CD11c (N418), CD11b (M1/70), and
F4/80 (BM8) were purchased from BD Biosciences. FITC-peanut agglutinin
(PNA) was purchased from Vector Laboratories. CellTracker Green CMFDA
(5-chloromethylfluorescein diacetate) and CellTracker Red CMTPX from
Molecular Probes were used to stain viable cultured cells in vitro. To quantifyfree apoptotic cells in culture or from tissues, Annexin V-FITC Apoptosis
Detection Kit from BD PharMingen was used. Apoptotic cells in tissues were
also identified by TUNEL reaction according to the instructions of the manu-
facturer with an In situ Cell Death Detection Kit from Roche. Fluorescent Latex
beads, carboxilate-modified polystyrene yellow-green (Sigma), and GFP-
E. coli (a gift from G. Cheng, UCLA) were used for phagocytosis assays.
Cell Culture and Transfections
Bone marrow-derived macrophages (BMDM) and thioglycolate (TG)-elicited
peritoneal macrophages were obtained as described (Castrillo et al., 2003b).
Macrophages were cultured in RPMI or DMEM containing 10% fetal bovine
serum (FBS, Omega Scientific). For ligand treatments, cells were cultured in
medium supplemented with 0.5% BSA and receptor ligands in DMSO vehicle.
RAW-LXRa and RAW-FLAG-LXRa stable cell line were generated by retroviral
transduction with a pBabe-puro-based expression vector as previously
described (Chen et al., 2006; Venkateswaran et al., 2000). RAW-Mer stable
cell lines were generated by cotransfection of a pCDNA-Mer expression vector
(kindly provided by D.K. Graham) along with a G418 resistance plasmid (Gra-
ham et al., 1995). Multiple clones were selected and analyzed for Mer mRNA
expression and two independent clones were chosen for analysis. Knockdown
studies were performed in RAW-LXRa cells with Amaxa Nucleofection kit
specific for mouse macrophages and different specific murine MER siRNAs
(Dharmacon) or nonspecific siRNA according to the instructions of the manu-
facturer. Transfection efficiency was determined by GFP-expressing cells. An
average of 50%–60% transfection efficiency was achieved with this method.
Studies with MER blocking antibody were performed in WT and LXR DKO
macrophages. 50 mg/ml of Mer antibody (R&D systems) was added to RPMI
medium for 3 hr before phagocytosis assays (see below).
In Vitro Phagocytosis Assays
In vitro phagocytosis assays with mouse macrophages were carried out
essentially as described (Hanayama et al., 2002; Scott et al., 2001; Yamauchi
et al., 2004). Primary peritoneal macrophages were recovered from mice
injected with 3% thyoglicolate for 3 days. Cells were pelleted and resuspended
in RPMI (Cambrex) medium suplemented with 10% FCS (Lonza) and 5 3 105
cells were plated on sterile glass coverslips. To generate apoptotic thymo-
cytes (AT), thymi from 3- to 4- week-old C57BL/6 mice were harvested and
mechanically disociated, filtered, pelleted, and resuspended in RPMI medium
supplemented with 10% FCS. Apoptosis was induced by treatment with 1 mM
of dexamethasone (Sigma) for 6 hr. This method results in 60%–80% thymo-
cyte apoptosis, as measured with FITC-AnnexinV staining (BD). AT were
washed twice with PBS and fluorescein labeled with CellTracker green (Invitro-
gen) according to the manufacturer’s instructions. Fluorescent AT were added
to peritoneal macrophages in a 5:1 ratio (ATs:macrophages) and cultured at
37C for 30, 60, or 90 min in RPMI supplemented with 10% FBS. After incuba-
tion with ATs, macrophages were gently washed several times with cold PBS
and Cell Dissociation Buffer, Enzyme Free PBS-based (Invitrogen) to remove
free apoptotic thymocytes as described (Krysko et al., 2006; Yamauchi
et al., 2004). Cells were then fixed with 2% paraformaldehyde, and phagocy-
tosis was scored with confocal fluorescent microscopy. Phagocytosis was
expressed as phagocytic index (PI): number of cells ingested per total number
of macrophages 3 100 (Fadok et al., 1998b; Hanayama et al., 2004). Alterna-
tively, thymocytes were stained with CellTracker red and macrophages were
visualized with F4/80 antibody. In some studies, macrophages were treated
with 1 mM synthetic LXR agonist (GW3965) in RPMI supplemented with
0.5% FCS prior to addition of apoptotic cells and phagocytosis assays were
performed as described above in RPMI containing 10% FBS. Latex beads
and bacterial phagocytosis were performed with 1 mm carboxilate-coated
fluorescent beads (Sigma) and GFP-E. coli, respectively, and cultured with
macrophages for 30 min. In some experiments, sterol content from apoptotic
cells was decreased by treating apoptotic thymocytes with methyl-b-cyclo-
dextrin (MbCD, Sigma). ATs were cultured with 5 mM of MbCD in RPMI for
1 hr and then proceed with the phagocytosis assay.
In Vivo Phagocytosis Assays
For in vivo peritoneal macrophage phagocytosis assays, 1 3 107 CFSE-
labeled apoptotic thymocytes were injected i.p. into 6- to 8-week-old wild-
type and LXR DKO, ApoE/, Abcg1/, Abca1 WT, or Abca1/ mice. MiceImmunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc. 255
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single-cell suspension of peritoneal flush was stained with anti-F4/80 and
CD19 to identify macrophage and B cell populations, respectively. Cells
were analyzed by flow cytometry (described below). Statistical analysis was
performed by Student’s t test.
For in vivo thymic phagocytosis assays, 4-week-old mice were injected i.p.
with 0.2 mg of dexamethasone per 25 g body weight in PBS (Sigma). After
24 hr, mice were sacrificed and thymi were extracted and mechanically disso-
ciated. Free apoptotic cells were determined with FITC-AnnexinV staining with
a Coulter Epics XL-MCL (Beckman Coulter). Additionally, cells were fixed and
permeabilized and total apoptotic cells were measured via the TUNEL reaction
(In Situ Cell Death Detection Kit from Roche). For transmission electron micros-
copy analysis, mice treated for 24 hr with dexamethasone were sacrificed and
perfused with fixation solution (2% glutaraldehyde). Thymi were harvested,
fixed with 2% OsO4, dehydrated, and embedded in epoxy resin. Ultra-thin
sections were stained with uranyl acetate and lead citrate and observed under
electron microscope at the ULPGC electron microscopy core facility.
Histology
Tissues were collected and fixed in 4% buffered formalin, dehydrated in
successive alcohol solutions, embedded in paraffin wax, and sectioned for
H&E staining. Alternatively, tissues were directly collected from the animal,
embedded in OCT compound (Tissue-Tek), and snap-frozen in liquid Nitrogen
and Isopentane. 4 mm frozen sections were air-dried, fixed with 4% parafor-
maldehyde, blocked with 6% BSA and 2% preimmune serum in PBS, and
stained with fluorescence-conjugated antibodies diluted in blocking solution;
nuclei were stained with DAPI (Vectashield mountain medium fluorescence
with DAPI, Vector). For non-fluorophore-conjugated antibodies, biotinylated
secondary antibodies were visualized by the streptavidin-biotin-peroxidase
method (Vectastain ABC Kit, Vector Laboratories) and stained with the crom-
ogen 3-30-diaminobenzidine tetrahydrochloride (DAB Substrate Kit for perox-
idase, Vector Laboratories). Nuclei were counterstained with hematoxilin.
TUNEL reaction (In Situ Cell Death Detection kit from Roche) was used to iden-
tify apoptotic cells in frozen sections from spleen, thymus, lung, and testis:
4 mm sections were fixed with 2% paraformaldehyde, permeabilized with
0.1% Triton X-100 in 0.1% sodium citrate, and stained with the TUNEL reac-
tion. Then, macrophages were identified in the same sections with rat anti-
mouse-CD68 (Serotec) and visualized with secondary antibody anti-rat-Alexa
Fluor 594 (Molecular Probes). Sections and pictures were observed under
a Zeiss LSM 5 PASCAL Laser Scaning Microscope (Carl Zeiss, Germany).
ELISA and Biochemical Parameters
The presence of antinuclear antibodies (via a Mesacup ANA test from MBL) and
autoantibodies directed against dsDNA and of histones were examined in serial
dilutions of mouse serum by ELISA as described in previously (Salvador et al.,
2002). In brief, 96-well flat-bottom plates (Nunc-immuno plate F96 MAXISORP)
were precoated with 2.5mg of poly-L-lysine (Sigma) for 1 hr at 37C. Plates were
incubated with 0.5mg/well of dsDNA, histone type II-S from calf thymus (Sigma)
overnight at 4C. After blocking the nonspecific sites with 5% FCS for 1 hr at
37C, mice serum samples were added for 3 hr at room temperature. Then
followed 1 hr of incubation with HRP-labeled goat anti-mouse IgG Fc-specific
(Jackson Immunoresearch) diluted 1:500. A substrate solution containing equal
volumes of Sigma Fast OPD peroxidase substrate was added. After incubation
of 5 min at room temperature, reaction was stopped with 50 ml of 3M H2SO4
solution and the plates were read at 492 nm in ELISA reader (Bio-Rad).
DNA, RNA, and Protein Analysis
Total RNA was harvested with TRIzol reagent (Invitrogen). Total RNA was
reverse-transcribed with random hexamers by using iScript reverse-transcrip-
tion reagents kit (Bio-Rad) according to manufacturer protocol. Real-time
quantitative PCR (SYBRgreen) assays were performed with an Applied Biosys-
tems 7900 sequencer detector as described previously (Joseph et al., 2003;
Laffitte et al., 2001). Expression was normalized to 36B4 expression. Primer
and probe sequences are available upon request. Statistical analysis of
mRNA expression data was performed via the Student’s t test. Probe and
primer sequences are available on request. Electrophoretic mobility shift assay
was performed as described previously (Laffitte et al., 2001). In brief, murine
LXRa and RXRa proteins were synthesized with the TnT T7 quick-coupled256 Immunity 31, 245–258, August 21, 2009 ª2009 Elsevier Inc.transcription/translation system (Promega). Reaction mixture containing
proteins and buffer was briefly preincubated with RXRa polyclonal antibody
(Santa Cruz Biotechnology) before addition of radiolabeled oligonucleotides
as indicated. The binding reactions were resolved on a pre-electrophoresed
1X TBE, 5% polyacrylamide gel. Oligonucleotides used were as follows (only
one strand shown): Mer LXRE primer: 50-ttcatgtgtatgctggggtaccca-30, Mer
Mutant LXRE: 50-ttcattttaatgcagtttaaccca-30, and SREBP1c LXRE: 50-cgctgg
ggttactggcggtcactgta-30. For northern blots, 10 mg of total RNA isolated
from cells was separated by gel electrophoresis, transferred to nylon
membranes, and hybridized with [a-32P]dCTP-labeled DNA probes as
described (Castrillo et al., 2003b).
Chromatin immunoprecipitation (ChIP) assays were performed essentially
as described (Hecht and Grunstein, 1999). In brief, RAW-LXRa or RAW-
FLAG- LXRa macrophages were cultured with GW3965 for 1 hr and fixed
with 1% formaldehyde. After cross-linking, cells were sonicated in order to
obtain DNA fragments of 300–1000 bp. Immunoprecipitation was performed
with the following antibodies: anti-NCoR (Affinity Bioreagents, Golden, CO),
rabbit anti-RNA PolII, anti-RXRa, anti-FLAG, and anti-Rabbit IgG (Santa
Cruz Biotechnology). Protein-DNA complexes were reverse cross-linked at
65C overnight and DNA was purified with a PCR purification kit (G&E Health-
care). Fractions of DNA were used for real-time quantitative PCR.
For western blot analysis, whole cell lysates were boiled and separated on
a SDS-PAGE gel. Proteins were transferred onto polyvinylidene difluoride
membrane (Amersham), blocked in TBS with 0.1% Tween20 and 5% milk,
and incubated with the following antibodies: rabbit anti-Mer and ABCG1
from Novus Biologicals, rabbit ABCA1 antisera kindly provided by M.L.
Fitzgerald (Fitzgerald et al., 2001) (MGH, Boston, MA), rabbit anti-ApoE from
AbCAM, and secondary goat anti-rabbit HRP from Amersham. Blots were
washed in TBS-T and visualized with ECL-Plus (Amersham Biosciences) and
Bio-Rad Chemi-Doc imaging system.
DNA Microarray Analysis
Total RNA was isolated from RAW264.7 macrophages ectopically expressing
LXRa (Venkateswaran et al., 2000) cultured with vehicle or GW3965 (1 mM) and
LG268 (100 nM). Transcriptional profiling was performed at the UCLA microar-
ray core facility with murine Affymetrix 430 2.0 microarrays. Data were
analyzed with GeneSpring and GeneChip Analysis Suite software (Affymetrix)
as described previously (Zelcer et al., 2007). Only statistically significant
expression differences are presented.
Flow Cytometry
Single-cell suspensions from lymph nodes and spleens were obtained from
mice and washed twice in staining buffer, resuspended, and incubated with
labeled antibodies diluted in staining buffer for 30 min at 4C. After incubation,
cells were washed in staining buffer and analyzed immediately. Intracellular
FoxP3 staining was performed as per manufacturer’s instruction (eBioscien-
ces). Cells were analyzed on FACSCalibur or LSRII (Becton Dickinson) with
FlowJo software (Treestar, Inc.). For in vivo thymic phagocytosis assay and
for in vitro apoptosis analysis of thymocytes, TUNEL reaction and FITC-Annex-
inV staining were analyzed on Coulter Epics XL-MCL (Beckman Coulter).
Statistical Analysis
Data were expressed as mean ± SD. Statistical analysis was performed with
Student’s t test for two samples. For multiple comparisons, data were evalu-
ated by one-way analysis of variance (ANOVA). Values of p < 0.05 were consid-
ered to be significant.
ACCESSION NUMBERS
Microarray data are available through the NCBI Gene Expression Omnibus
database with accession code GSE17088.
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